Correlates of GERD Symptom Severity
2020年12月22日 更新者：Michelle Dossett, MD, PhD, MPH、Massachusetts General Hospital
Physiologic and Behavioral Correlates of GERD Symptom Severity
This is a pilot study measuring physiologic and behavioral correlates of symptom severity in adult patients with gastroesophageal reflux disease (GERD).
調査の概要
状態
完了
条件
詳細な説明
Subjects will complete questionnaires regarding their GERD-related symptoms and have a visit with a study clinician regarding their symptoms.
We will measure heart rate variability and galvanic skin response in patients during the visits and video record the visits.
Subjects will complete a daily GERD symptom diary for 2 weeks and then return to the study center to complete additional questionnaires and an exit interview.
研究の種類
観察的
入学 (実際)
24
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- Massachusetts General Hospital
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
21年～70年 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
全て
サンプリング方法
非確率サンプル
調査対象母集団
Adults with active GERD-related symptoms.
説明
Inclusion Criteria:
- Adults ages 21-70 years old
- Heartburn symptoms 3 or more days per week with an average daily symptom severity of 3 or more on a 7 day baseline symptom diary
- English language proficiency
- Willingness to be videotaped and connected to physiologic monitoring devices during the visit
Exclusion Criteria:
- Diagnosis of Crohn's disease, systemic sclerosis, known active ulcer disease, gastric cancer, or untreated/active Barrett's esophagitis based on subject self-report and/or medical record review
- Heavy alcohol use (> 6 drinks/week for women and > 13 drinks/week for men)
- Pregnant women.
- Dementia or significant memory difficulties
- Severe, unstable psychiatric disease
- Greater than 15 doses of nonsteroidal anti-inflammatory drugs (NSAIDS) within the prior 30 days (aspirin ≤ 325 mg daily permitted) or ongoing NSAID use at a level deemed likely to interfere with the study
- Failure to complete the baseline symptom diary for at least 6 of 7 days
- Change in GERD treatment regimen within the last 2 weeks (subjects may use antacids, H2 receptor blockers, and/or proton pump inhibitors as long as they are symptomatic on a stable regimen)
- Allergy to adhesives
- Inability to provide informed consent
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
GERD Patients
Subjects with active GERD symptoms.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Association of Change in Patient's GSR From Beginning to End of Study Visit With GERD Symptom Severity 2 Weeks Later
時間枠：Beginning to end of study visit (1 hour or less for change in GSR)
|
Galvanic skin response (GSR) was measured with a device from ADInstruments during the baseline study visit.
Values ranged from 0.93 - 12 micro-Siemens (μS).
Change in GSR was calculated as mean value of GSR for the first 2 minutes of the study visit minus mean value of GSR for the last 2 minutes of the study visit.
|
Beginning to end of study visit (1 hour or less for change in GSR)
|
|
Association of Change in Patient's High Frequency HRV From Beginning to End of Study Visit With GERD Symptom Severity 2 Weeks Later
時間枠：Beginning to end of study visit (1 hour or less for change in HRV/RMSSD)
|
Heart rate variability (HRV) was measured using a device from ADInstruments gathering data at 256 Hz.
We used the RMSSD (Root Mean Square of the Successive Differences) value as a proxy for high frequency HRV.
Measured values ranged from 0 - 150 msec.
Change in high frequency HRV was calculated as the RMSSD value for the first 5 minutes of the study visit minus the RMSSD value for the last 5 minutes of the study visit.
|
Beginning to end of study visit (1 hour or less for change in HRV/RMSSD)
|
|
Correlation Between Concordance in GSR Between Patient and Physician During the Study Visit and Percent Change in Patients' GERD Symptoms Over 2 Weeks
時間枠：Beginning to end of study visit (1 hour or less for concordance between patient and physician GSR)
|
Concordance in galvanic skin response (GSR) between patient and physician was calculated using an established approach (Marci CD, 2007; PMID 17299296) to create a single index value for the visit.
The natural logarithm of this value was taken to reduce skew.
A value greater than 0 means more than 50% concordance in the data, a value less than zero means less than 50% concordance in the data.
|
Beginning to end of study visit (1 hour or less for concordance between patient and physician GSR)
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Post GERD Symptom Severity
時間枠：2 weeks (baseline and 2 week follow-up)
|
GERD symptom severity at follow-up was assessed by self-report on a 7-day symptom diary (symptoms collected days 8-14 after the study visit).
Possible daily scores ranged from 0-12 with higher scores indicating more severe symptoms (sum of daytime heartburn, nighttime heartburn, and acid regurgitation symptoms each rated 0-4 in severity [none, mild, moderate, severe, very severe]).
Daily scores across the 7 days were averaged to create the Post GERD symptom severity score.
Adapted from: Miner P, et.
al. Am J Gastroenterol. 2002.
PMID: 12094846.
|
2 weeks (baseline and 2 week follow-up)
|
|
Percent Change in Patient's GERD Symptoms
時間枠：2 weeks (baseline and 2 week follow-up)
|
Percent change in patient's GERD symptoms was calculated as: (post GERD symptom severity - baseline GERD symptom severity) / baseline GERD symptom severity*100. GERD symptom severity scores were averaged across 7 day baseline and follow-up periods from a symptom diary (adapted from Miner P, 2002; PMID 12094846). Scores ranged from 0-12 with higher scores indicating more severe symptoms (sum of daytime heartburn, nighttime heartburn, and acid regurgitation each rated 0-4 in severity [none, mild, moderate, severe, very severe]). |
2 weeks (baseline and 2 week follow-up)
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
捜査官
- 主任研究者：Michelle Dossett, MD, PHD, MPH、Massachusetts General Hospital
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2017年5月22日
一次修了 (実際)
2019年5月3日
研究の完了 (実際)
2019年5月7日
試験登録日
最初に提出
2016年12月20日
QC基準を満たした最初の提出物
2017年1月11日
最初の投稿 (見積もり)
2017年1月13日
学習記録の更新
投稿された最後の更新 (実際)
2021年1月15日
QC基準を満たした最後の更新が送信されました
2020年12月22日
最終確認日
2020年12月1日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。